Atlas Trials

Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer

Clinical trial NCT01727869 · COMPLETED

Trial details

NCT number
NCT01727869
Sponsor
Regeneron Pharmaceuticals
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Cancer
Start date
2012-10-01
Primary completion
2015-01-01
Enrollment
56

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.